Secondary amyloidosis epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shaghayegh Habibi, M.D.[2] Sahar Memar Montazerin, M.D.[3]

Overview

The incidence of AA amyloidosis is approximately 0.16 per 100,000 individuals in 2008 in the United kingdom. The mortality rate of systemic amyloidosis is approximately 100 per 100,000 deaths in developed countries. Secondary amyloidosis more commonly affects children. Men are more commonly affected by amyloidosis than women.

Epidemiology and Demographics

Incidence

The incidence of AA amyloidosis is approximately 0.16 per 100,000 individuals in 2008 in the United kingdom.^[1]

Prevalence

The prevalence of AA amyloidosis is 5,000 to 10,000 per 100,000 individuals with chronic inflammatory process per year worldwide.^[2]

Mortality rate

The mortality rate of systemic amyloidosis is approximately 100 per 100,000 deaths in developed countries.^[3]

Age

Secondary amyloidosis more commonly affects children.^[4]

Race

There is no racial predilection to secondary amyloidosis.

Gender

Men are more commonly affected by amyloidosis than women.^[5]

References

↑ Lane T, Pinney JH, Gilbertson JA, Hutt DF, Rowczenio DM, Mahmood S, Sachchithanantham S, Fontana M, Youngstein T, Quarta CC, Wechalekar AD, Gillmore JD, Hawkins PN, Lachmann HJ (September 2017). “Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centre”. Amyloid. 24 (3): 162–166. doi:10.1080/13506129.2017.1342235. PMID 28686088.
↑ Koivuniemi, Riitta; Paimela, Leena; Suomalainen, Risto; Törnroth, Tom; Leirisalo-Repo, Marjatta (2009). “Amyloidosis is frequently undetected in patients with rheumatoid arthritis”. Amyloid. 15 (4): 262–268. doi:10.1080/13506120802524676. ISSN 1350-6129.
↑ Pepys MB (2006). “Amyloidosis”. Annu. Rev. Med. 57: 223–41. doi:10.1146/annurev.med.57.121304.131243. PMID 16409147.
↑ Bilginer, Yelda; Akpolat, Tekin; Ozen, Seza (2011). “Renal amyloidosis in children”. Pediatric Nephrology. 26 (8): 1215–1227. doi:10.1007/s00467-011-1797-x. ISSN 0931-041X.
↑ Shin YM (March 2011). “Hepatic amyloidosis”. Korean J Hepatol. 17 (1): 80–3. doi:10.3350/kjhep.2011.17.1.80. PMC 3304630. PMID 21494083.

Template:WH Template:WS

[pmid28686088-1] Lane T, Pinney JH, Gilbertson JA, Hutt DF, Rowczenio DM, Mahmood S, Sachchithanantham S, Fontana M, Youngstein T, Quarta CC, Wechalekar AD, Gillmore JD, Hawkins PN, Lachmann HJ (September 2017). “Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centre”. Amyloid. 24 (3): 162–166. doi:10.1080/13506129.2017.1342235. PMID 28686088.

[KoivuniemiPaimela2009-2] Koivuniemi, Riitta; Paimela, Leena; Suomalainen, Risto; Törnroth, Tom; Leirisalo-Repo, Marjatta (2009). “Amyloidosis is frequently undetected in patients with rheumatoid arthritis”. Amyloid. 15 (4): 262–268. doi:10.1080/13506120802524676. ISSN 1350-6129.

[pmid16409147-3] Pepys MB (2006). “Amyloidosis”. Annu. Rev. Med. 57: 223–41. doi:10.1146/annurev.med.57.121304.131243. PMID 16409147.

[BilginerAkpolat2011-4] Bilginer, Yelda; Akpolat, Tekin; Ozen, Seza (2011). “Renal amyloidosis in children”. Pediatric Nephrology. 26 (8): 1215–1227. doi:10.1007/s00467-011-1797-x. ISSN 0931-041X.

[pmid21494083-5] Shin YM (March 2011). “Hepatic amyloidosis”. Korean J Hepatol. 17 (1): 80–3. doi:10.3350/kjhep.2011.17.1.80. PMC 3304630. PMID 21494083.

[1]

[2]

[3]

[4]

[5]